Evidence map›Paper›PMID 41954342›Full record

ArticlePathologica2025

Eltjona Mane, Giulia Cursano, Konstantinos Venetis, Chiara Frascarelli, Francesco Pepe, Mariantonia Nacchio, Lucia Palumbo, Pasquale Pisapia, Elisa De Camilli, Isabella Castellano and 16 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Pathologica, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Liquid biopsy in solid tumours: expert opinion paper of the European society of pathology.Virchows Archiv : an international journal of pathology · 2026
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

26 authors.

Eltjona ManeDivision of Pathology, European Institute of Oncology IRCCS, Milan, Italy.
Giulia CursanoDivision of Pathology, European Institute of Oncology IRCCS, Milan, Italy.
Konstantinos VenetisDivision of Pathology, European Institute of Oncology IRCCS, Milan, Italy.
Chiara FrascarelliDivision of Pathology, European Institute of Oncology IRCCS, Milan, Italy.
Francesco PepeDepartment of Public Health, Federico II University of Naples, Naples, Italy.
Mariantonia NacchioDepartment of Public Health, Federico II University of Naples, Naples, Italy.
Lucia PalumboDepartment of Public Health, Federico II University of Naples, Naples, Italy.
Pasquale PisapiaDepartment of Public Health, Federico II University of Naples, Naples, Italy.
Elisa De CamilliDivision of Pathology, European Institute of Oncology IRCCS, Milan, Italy.
Isabella CastellanoUnit of Pathology, Department of Medical Sciences, City of Health and Science University Hospital, University of Turin, Turin, Italy.
Bruna CerbelliDepartment of Medical-Surgical Sciences and Biotechnologies Sapienza University of Rome, Rome, Italy.
Leopoldo CostarelliUnit of Pathology, San Giovanni-Addolorata Hospital, Rome, Italy.
Giulia d'AmatiDepartment of Medical-Surgical Sciences and Biotechnologies Sapienza University of Rome, Rome, Italy.
Antonio RizzoDivision of Pathology, Clinical Institute Humanitas Catania, Misterbianco (CT), Italy.
Alfredo SantinelliUnit of Anatomic Pathology, Azienda Sanitaria Territoriale di Pesaro-Urbino, Pesaro, Italy.
Cristian ScatenaDivision of Pathology, Department of Translational Research and New Technologies in Medicine and Surgery, University of Pisa, Pisa, Italy.
Carmen CriscitielloDepartment of Oncology and Hemato-Oncology, University of Milan, Milan, Italy.
Carmine De AngelisClinical and Translational Oncology, Scuola Superiore Meridionale, Naples, Italy.
Maria Vittoria DieciDepartment of Surgery, Oncology and Gastroenterology, University of Padova, Padova, Italy.
Giancarlo TronconeDepartment of Public Health, Federico II University of Naples, Naples, Italy.
Giuseppe CuriglianoDepartment of Oncology and Hemato-Oncology, University of Milan, Milan, Italy.
Giuseppe VialeDivision of Pathology, European Institute of Oncology IRCCS, Milan, Italy.
Elena Guerini-RoccoDivision of Pathology, European Institute of Oncology IRCCS, Milan, Italy.
Umberto MalapelleDepartment of Public Health, Federico II University of Naples, Naples, Italy.
Nicola FuscoDivision of Pathology, European Institute of Oncology IRCCS, Milan, Italy.
PIK3CA in breast cancer GIPaM/PMMP cooperative group

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The management of hormone receptor-positive/HER2-negative (HR+/HER2-) metastatic breast cancer (MBC) relies on molecular testing to inform treatment decisions.

Indexed as

Biomarkers, TumorBreast NeoplasmsClass I Phosphatidylinositol 3-KinasesLaboratories, ClinicalCross-Sectional StudiesErb-b2 Receptor Tyrosine KinasesFemaleHumansItalyMutationReceptors, EstrogenReceptors, ProgesteroneBiomarkers, TumorClass I Phosphatidylinositol 3-KinasesERBB2 protein, humanErb-b2 Receptor Tyrosine KinasesPIK3CA protein, humanReceptors, EstrogenReceptors, ProgesteroneHR+/HER2−metastatic breast cancermolecular diagnosticsnext-generation sequencing (NGS)PIK3CA testingprecision oncology

Identifiers

PMID41954342
PMCPMC13094337

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.